Search

606 Result(s)
Sort by

university-of-medical-excellence-harvard

university-of-medical-excellence-harvard

A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Living with pulmonary fibrosis and finding hope

Living with pulmonary fibrosis and finding hope

From caregiver to co-founder of the European Pulmonary Fibrosis Federation, Liam Galvin shares about his experience, and the impact of ongoing research
Phase 3 studies survodutide obesity and overweight

Phase 3 studies survodutide obesity and overweight

Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Partnering for innovation in animal health

Partnering for innovation in animal health

Collaboration with external partners is a fundamental part of our innovation strategy in Animal Health. Learn more about the partners we are looking for.
The GPP Forum

The GPP Forum

The generalized pustular psoriasis (GPP) Forum - a multistakeholder event collaborating for a new vision for people living with GPP
Family owned

Family owned

Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!
The power of our people

The power of our people

Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
survodutide top-line results MASH fibrosis

survodutide top-line results MASH fibrosis

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
collaboration-kings-college-london

collaboration-kings-college-london

Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Innovation from within

Innovation from within

Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.